Ignite Creation Date:
2024-05-05 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00454857
Status:
COMPLETED
Last Update Posted:
2013-11-26
First Post:
2007-03-29
Brief Title:
Retrospective Prospective Observational Study of Patients With Immune Idiopathic Thrombocytopenic Purpura ITP
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Prospective Observational Descriptive Study and Retrospective Chart Review of Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP
Status:
COMPLETED
Status Verified Date:
2013-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multi-center prospective observational descriptive study complemented by a retrospective chart review Patients diagnosed with ITP and currently treated for ITP by a hematologist or hematologist-oncologist will be recruited from community-based clinics and academicreferral centers They will be followed prospectively for a period of 12 months At inception participants charts will also be reviewed from the date of enrollment retrospectively to the date of diagnosis or the previous 36 months whichever is less
Detailed Description:
Time Perspective 12 months prospective chart review study with a retrospective chart review for a period up to 36 months from the start of the study since the date of diagnosis for ITP
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None